HK Stock Market Move | VIVA BIOTECH (01873) surged over 5%, with Langhua Pharmaceutical's CDMO's two new commercialized projects making significant contributions to its performance.

VIVA BIOTECH (01873) rose over 5%, reaching an increase of 5.17% at the time of publication, priced at HK$1.425, with a transaction volume of HK$7.5405 million. In terms of news, VIVA BIOTECH recently disclosed its performance for the first half of the year. CMSC pointed out that in 26H1, the company's revenue increased by 21.0% year-on-year, mainly due to the significant contribution from two new commercialization projects of Langhua Pharmaceutical's CDMO. Specifically, in 26H1, Langhua Pharmaceutical's revenue was 601 million yuan, up 47.0% year-on-year (fixed exchange rate +52.2%). The two major new commercialization projects are advancing steadily; the peptide project has been commercialized and has entered the stocking and ramp-up phase, while the small molecule project is in the PPQ production stage and is expected to be commercially launched in 2027. Both projects will become the core driving force for the continuous growth of CDMO in the coming years.